Milan, August 14th 2026 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumors, called YntraDose®, announced today the publication in Nuclear Medicine and Biology of a peer-reviewed article entitled: “In vivo preclinical evaluation of YntraDose™ in pig’s lung: A pilot…

Milan, November 12, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumors, announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has approved the Clinical Trial Application for YntraDose™ in unresectable Locally…

Milan, September 22, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumors, called YntraDose®, announced today the succession of its Chief Executive Officer (“CEO”), Dr. Colin Story, to Mr. Alexis Peyroles, who was appointed as CEO.…

Milan, May 27th 2025 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumors, called YntraDose®, announced today that an abstract was published by the American Society of Clinical Oncology (ASCO) entitled: “Preclinical study of safety and efficacy in vivo of…

Milan, February 20th 2025 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumors, called YntraDose®, announced today that it has entered into an agreement for the exclusive global supply of BioGlue® for use in YntraDose. Artivion, Inc. (“Artivion”) manufactures, markets,…

Milan, December 16th 2024 - BetaGlue® Therapeutics S.p.A. (“BetaGlue”) an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumors, called YntraDose®, announced today that the ENEA-Tech and Biomedical Foundation (“ENEA-Tech”) has invested €6m bringing the total raised in the current funding round to €24m. This…

Milan, June 6, 2024 – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage radiotherapy company developing novel products for the personalised treatment of solid tumor cancers today announces the closing of an €8m equity financing round. The round included both existing and new investors and was led by Neva SGR S.p.A., the venture capital arm…